Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 202

    1.

    Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.

    Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, Huntsman DG, Gelmon KA.

    Breast Cancer Res. 2008;10(1):R6. Epub 2008 Jan 14.

    PMID:
    18194560
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators.

    Ravdin PM, De Laurentiis M, Vendely T, Clark GM.

    J Natl Cancer Inst. 1994 Dec 7;86(23):1771-5.

    PMID:
    7966415
    [PubMed - indexed for MEDLINE]
    3.

    Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.

    Escobar PF, Patrick RJ, Rybicki LA, Hicks D, Weng DE, Crowe JP.

    Ann Surg Oncol. 2006 Jun;13(6):783-7. Epub 2006 Apr 12.

    PMID:
    16604475
    [PubMed - indexed for MEDLINE]
    4.

    Significance of axillary lymph node metastasis in primary breast cancer.

    Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK.

    J Clin Oncol. 1999 Aug;17(8):2334-40. Erratum in: J Clin Oncol 1999 Oct;17(10):3365.

    PMID:
    10561295
    [PubMed - indexed for MEDLINE]
    5.

    Prognostic significance of axillary node and infraclavicular lymph node status after mastectomy.

    Kuru B, Camlibel M, Dinc S, Gulcelik MA, Alagol H.

    Eur J Surg Oncol. 2003 Dec;29(10):839-44.

    PMID:
    14624774
    [PubMed - indexed for MEDLINE]
    6.

    CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.

    Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Rydén L, Gallagher WM, O'Brien SL.

    Clin Cancer Res. 2006 Nov 1;12(21):6421-31.

    PMID:
    17085655
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].

    Guan Y, Xu BH, Li Q, Zhang P, Zhao LM, Yuan P, Wang JY.

    Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):77-81. Chinese.

    PMID:
    18353207
    [PubMed - indexed for MEDLINE]
    8.

    Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

    von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

    Breast Cancer Res. 2008;10(2):R30. Epub 2008 Apr 1.

    PMID:
    18380893
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

    J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27.

    PMID:
    18505968
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

    Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.

    PMID:
    18925950
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials.

    Kyndi M, Sørensen FB, Knudsen H, Alsner J, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.

    Breast Cancer Res. 2008;10(2):R24. Epub 2008 Mar 20.

    PMID:
    18355402
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.

    Loya A, Guray M, Hennessy BT, Middleton LP, Buchholz TA, Valero V, Sahin AA.

    Cancer. 2009 Apr 15;115(8):1605-12.

    PMID:
    19197997
    [PubMed - indexed for MEDLINE]
    Free Article
    13.

    Disease-free survival and prognostic significance of metastatic lymph node ratio in T1-T2 N positive breast cancer patients. A population registry-based study in a European country.

    Martinez-Ramos D, Escrig-Sos J, Alcalde-Sanchez M, Torrella-Ramos A, Salvador-Sanchis JL.

    World J Surg. 2009 Aug;33(8):1659-64.

    PMID:
    19488815
    [PubMed - indexed for MEDLINE]
    14.

    Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.

    Göhring UJ, Ahr A, Scharl A, Weisner V, Neuhaus W, Crombach G, Holt JA.

    J Soc Gynecol Investig. 1995 Jul-Aug;2(4):653-9.

    PMID:
    9420872
    [PubMed - indexed for MEDLINE]
    15.

    Prognostic value of different factors in breast carcinoma.

    Hlupić L, Jakić-Razumović J, Bozikov J, Corić M, Belev B, Vrbanec D.

    Tumori. 2004 Jan-Feb;90(1):112-9.

    PMID:
    15143983
    [PubMed - indexed for MEDLINE]
    16.
    17.

    A simple index to predict prognosis independent of axillary node information in breast cancer.

    Seshadri R, Horsfall DJ, McCaul K, Leong AS.

    Aust N Z J Surg. 1997 Nov;67(11):765-70.

    PMID:
    9396991
    [PubMed - indexed for MEDLINE]
    18.

    The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis.

    Chen SL, Hoehne FM, Giuliano AE.

    Ann Surg Oncol. 2007 Dec;14(12):3378-84. Epub 2007 Sep 26.

    PMID:
    17899293
    [PubMed - indexed for MEDLINE]
    19.

    Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis.

    Ceriani RL, Chan CM, Baratta FS, Ozzello L, DeRosa CM, Habif DV.

    Int J Cancer. 1992 May 28;51(3):343-54.

    PMID:
    1592525
    [PubMed - indexed for MEDLINE]
    20.

    Variation of the prognostic significance of HER-2 expression in breast cancer according to tumor size.

    Swede H, Moysich KB, Winston JS, Hurd TC, Edge SB, Romero-Gutierrez M, Brooks JS, Michalek AM.

    Breast J. 2003 Mar-Apr;9(2):98-105.

    PMID:
    12603382
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk